CONCOMITANT USE OF STRONG CYP3A4 INHIBITORS (SUCH AS BOCEPREVIR, CLARITHROMYCIN, CONIVAPTAN, INDINAVIR, ITRACONAZOLE, KETOCONAZOLE, LOPINAVIR/RITONAVIR, MIBEFRADIL, NEFAZODONE, NELFINAVIR, POSACONAZOLE, RITONAVIR, SAQUINAVIR, TELAPREVIR, TELITHROMYCIN, TIPRANAVIR/RITONAVIR, VORICONAZOLE) WITH LOMITAPIDE IS CONTRAINDICATED. CONCOMITANT USE OF MODERATE CYP3A4 INHIBITORS (SUCH AS AMPRENAVIR, APREPITANT, ATAZANAVIR, CIPROFLOXACIN, CRIZOTINIB, DARUNAVIR/RITONAVIR, DILTIAZEM, ERYTHROMYCIN, FLUCONAZOLE, FOSAMPRENAVIR, IMATINIB, VERAPAMIL) WITH LOMITAPIDE IS ALSO CONTRAINDICATED.
PATIENTS MUST AVOID GRAPEFRUIT JUICE WHILE TAKING JUXTAPID
WEAK CYP3A4 INHIBITORS (SUCH AS ALPRAZOLAM, AMIODARONE, AMLODIPINE, ATORVASTATIN, BICALUTAMIDE, CILOSTAZOL, CIMETIDINE, CYCLOSPORINE, FLUOXETINE, FLUVOXAMINE, GINKGO, GOLDENSEAL, ISONIAZID, LAPATINIB, NILOTINIB, PAZOPANIB, RANITIDINE, RANOLAZINE, TICAGRELOR, ZILEUTON) CAN INCREASE LOMITAPIDE EXPOSURE APPROXIMATELY 2-FOLD. THE MAXIMUM RECOMMENDED DOSAGE IS 30 MG DAILY EXCEPT WHEN COADMINISTERED WITH ORAL CONTRACEPTIVES, IN WHICH CASE THE MAXIMUM RECOMMENDED LOMITAPIDE DOSAGE IS 40 MG DAILY.
LOMITAPIDE INCREASES PLASMA CONCENTRATIONS OF WARFARIN.
LOMITAPIDE APPROXIMATELY DOUBLES THE EXPOSURE OF SIMVASTATIN, LOVASTATIN; THEREFORE, THE RECOMMENDED DOSE OF SIMVASTATIN SHOULD BE REDUCED BY 50%.
LOMITAPIDE IS AN INHIBITOR OF P-GLYCOPROTEIN (P-GP). COADMINISTRATION OF LOMITAPIDE WITH P-GP SUBSTRATES (SUCH AS ALISKIREN, AMBRISENTAN, COLCHICINE, DABIGATRAN ETEXILATE, DIGOXIN, EVEROLIMUS, FEXOFENADINE, IMATINIB, LAPATINIB, MARAVIROC, NILOTINIB, POSACONAZOLE, RANOLAZINE, SAXAGLIPTIN, SIROLIMUS, SITAGLIPTIN, TALINOLOL, TOLVAPTAN, TOPOTECAN) MAY INCREASE THE ABSORPTION OF P-GP SUBSTRATES. DOSE REDUCTION OF THE P-GP SUBSTRATE SHOULD BE CONSIDERED WHEN USED CONCOMITANTLY WITH LOMITAPIDE.